Page 99 - 2019_11 Resto del Mondo-web

Distinguishing ET JAK2V617F from PV
polycythemia vera: caveat utilitor. Leuk
Lymphoma. 2015;56(6):1540-1541.
13. Margolskee E, Orazi A, Krichevsky S, Silver RT. Evaluation of bone marrow morpholo- gy is essential for assessing disease status in interferon-treated polycythemia vera patients. Haematologica. 2017;102(3):e97-
e99.
14. Alvarez-Larran A, Ancochea A, Garcia M,
et al. WHO-histological criteria for myelo- proliferative neoplasms: reproducibility, diagnostic accuracy and correlation with gene mutations and clinical outcomes. Br J Haematol. 2014;166(6):911-919.
15. Ellis JT, Silver RT, Coleman M, Geller SA. The bone marrow in polycythemia vera. Semin Hematol. 1975;12(4):433-444.
16. Wilkins BS, Erber WN, Bareford D, et al. Bone marrow pathology in essential throm- bocythemia: interobserver reliability and utility for identifying disease subtypes.
Blood. 2008:111(1):60-70.
17. Spivak J. Polycythemia Vera. Curr Treat
Options Oncol. 2018;19(2):12.
18. Silver RT, Krichevsky S, Cross NCP.
Evaluation of serum erythropoietin values as defined by 2016 World Health Organization criteria for the diagnosis of polycythemia vera. Leuk Lymphoma. 2017;58(11):2768-2769.
19. Ancochea A, Alvarez-Larran A, Morales- Indiano C, et al. The role of serum erythro- poietin level and JAK2 v617f allele burden in the diagnosis of polycythemia vera. Br J Haematol. 2014;167(3):411-417.
20. Rumi E, Pietra D, Ferretti V, et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substan- tially different clinical course and out- comes. Blood. 2014;123(10):1544-1551.
21. "Laboratory Testing Information - Erythropoietin." RSS 20 In Focus. ARUP
Laboratories, Web. 28 Feb. 2013. http://www.aruplab.com/guides/ug/tests/0 050227.jsp>.
22. Price GL, Davis KL, Karve S, Pohl G, Walgren RA. Survival Patterns in United States (US) Medicare Enrollees with Non- CML Myeloproliferative Neoplasms (MPN). PLoS One. 2014;9(3):e90299.
23. Michiels JJ, Medinger M, Raeve HD, et al. Increased erythrocyte count on top of bone marrow histology but not serum EPO level or JAK2 mutation load discriminates between JAK2V617F mutated essential thrombocythemia and polycythemia vera. J Hematol Thromb Dis. 3:S1-001.
24. Pearson TC, Guthrie DL, Simpson J, et al. Interpretation of measured red cell mass and plasma volume in adults: Expert Panel on Radionuclides of the International Council for Standardization in Haematology. Br J Hematol. 1995;89(4): 745-756.
haematologica | 2019; 104(11)
2205